ZY
Therapeutic Areas
Jiangsu Hengrui Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Camrelizumab (SHR-1210) | Multiple Cancers (NSCLC, HCC, ESCC) | Approved/Phase III |
| Pyrotinib (SHR-1258) | HER2+ Breast Cancer | Approved |
| Famitinib (SHR-1020) | Gastrointestinal Stromal Tumor (GIST) | Approved |
| SHR-1701 | Non-small Cell Lung Cancer | Phase II/III |
| SHR-A1811 | HER2+ Solid Tumors | Phase III |
| SHR-1316 | Small Cell Lung Cancer | Phase III |
| SHR-4640 | Gout | Phase III |
| SHR-1209 | Hypercholesterolemia | Phase III |
Leadership Team at Jiangsu Hengrui Medicine
SP
Sun Piaoyang
Chairman of the Board
DH
Dai Hongjun
Global R&D President
ZL
Zhang Lianshan
Chief Medical Officer